Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 421 of 5804
-
Stem cells and immunotherapy join forces against childhood brain tumors
Disease control OngoingThis is a Phase I study of ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) plus nivolumab in pediatric patients with histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG, WHO Grade III or IV astrocytoma, oligodendrogliomas, oligoastrocytomas, e…
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental CAR-T therapy takes on lupus and more
Disease control Recruiting nowAn Exploratory, Single-Arm, Open-Label, Dose-Escalation Study of the Safety, Tolerability, PK, PD, and Efficacy of Anti-CD19/BCMA Universal CAR-T Therapy RD06-05 in Autoimmune Diseases (including SLE/LN, AAV/AAGN, Anti-GBM, MN, SSc, and IIM).
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Home care plus nutrition may cut post-hospital deaths in HIV — a trial puts it to the test
Disease control Recruiting nowPeople living with HIV (PLWH) are at high risk of poor health outcomes after being discharged from the hospital. This study is designed to test whether providing structured care at home-either with or without nutritional support-can help reduce the risk of death within six months…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Should MDS patients get chemo before a stem cell transplant? new trial aims to find out.
Disease control Recruiting nowThis study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 26, 2026 15:28 UTC
-
New eczema drug shows promise for kids in Late-Stage trial
Disease control Recruiting nowThis research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the f…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo aims to knock out stubborn lung bug
Disease control Recruiting nowThe goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are: Does adding contezolid to standard regimen further decre…
Phase: PHASE4 • Sponsor: Bin Cao • Aim: Disease control
Last updated Jun 26, 2026 18:25 UTC
-
New chemo regimen aims to boost survival in kids with down syndrome and leukemia
Disease control Recruiting nowThis prospective non-randomized multicenter trial created based on protocol ML DS 2006 and aimed at standardization of current therapy approaches and creating a national network for diagnostic, treatment and monitoring of children (0-18 years) with AML and Down syndrome in Russia…
Phase: PHASE3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for myeloma: alternating drug cocktail aims for deeper remission
Disease control Recruiting nowThe purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug duo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study is an open, multicenter phase I/II clinical study. The entire study is divided into three stages: dose escalation, dose expansion, and efficacy expansion. Objective: To evaluate the objective response rate (ORR), safety and tolerability of the combination of SHR-1501 a…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill could help hepatitis b patients who Don't respond to standard care
Disease control Recruiting nowThis study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment.
Phase: PHASE3 • Sponsor: Fujian Akeylink Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can aspirin and strong statins shield hearts with heavy calcium buildup?
Prevention Recruiting nowThe primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with seve…
Phase: PHASE4 • Sponsor: Jung-min Ahn • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
Twice-Yearly shot aims to cut heart attacks and amputations
Disease control Recruiting nowV-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an ad…
Phase: PHASE4 • Sponsor: Duke University • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New CAR-T therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowA Clinical Study to Explore the Safety, Efficacy, and Cellular Metabolic Dynamics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia.
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
AI reads your heartbeat to catch silent killer in lung patients
Diagnosis Recruiting nowMOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
Phase: NA • Sponsor: Tempus AI • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
New vaccine aims to boost immunity against advanced cervical cancer
⭐️ VACCINE ⭐️ Recruiting nowA Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 03, 2026 00:00 UTC
-
New cocktail aims to shrink stomach tumors before surgery
Disease control Recruiting nowNeoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 26, 2026 16:10 UTC
-
New hope for older leukemia patients: gentler chemo shows promise
Disease control Recruiting nowAcute lymphoblastic leukemia (ALL) is characterized by the abnormal proliferation of immature precursor cells, disrupting normal hematopoiesis and causing severe anemia and thrombocytopenia due to genetic mutations. Conventional treatment with intensive chemotherapy is limited fo…
Sponsor: Hospital General de Mexico • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New malaria vaccine shows promise in early human trial
⭐️ VACCINE ⭐️ OngoingThis randomized, double-blind, placebo-controlled, Phase 1 trial will enroll up to 22 malaria-naïve, adult participants to test safety, tolerability, immunogenicity, and efficacy of the genetically attenuated Plasmodium falciparum sporozoite vaccine (PfSPZ-LARC2) Vaccine. PfSPZ-L…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
New combo therapy before surgery shows promise for tough esophageal cancer
Disease control Recruiting nowEffective systemic therapy such as nivolumab as an adjuvant therapy has been demonstrated to improve the outcomes of patients receiving neoadjuvant chemoradiotherapy (CRT) for locoregional esophageal cancer. A more effective systemic therapy with anti-PD-1 or anti-PD-L1 immune ch…
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Electric shocks + chemo: new hope for inoperable tumors?
Disease control Recruiting nowThis is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous m…
Phase: NA • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC